同: VSD

WordNet

the state of being certain that adverse effects will not be caused by some agent under defined conditions; "insure the safety of the children"; "the reciprocal of safety is risk"
a score in American football; a player is tackled behind his own goal line
a safe place; "He ran to safety" (同)refuge
immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum

PrepTutorEJDIC

〈U〉(…からの)『安全』,無事《+『from』(『against』)+『名』》 / (また『safety catch』)〈U〉(銃などの)安全装置 / 〈C〉(アメリカンフットボールで)セーフティー(クォータバックなどのボールを持っている選手が自軍のエンド・ゾーン内にタックルされること。2得点。)
牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/24 16:12:04」(JST)

wiki en

The Vaccine Safety Datalink Project (VSD) was established in 1990 by the United States Centers for Disease Control and Prevention (CDC) to study the adverse effects of vaccines.

Four large health maintenance organizations, including Kaiser Permanente, were initially recruited to provide the CDC with medical data on vaccination histories, health outcomes, and subject characteristics. The VSD database contains data compiled from surveillance on more than seven million Americans, including about 500,000 children from birth through age six years (2% of the U.S. population in this age group).^[1]

The VSD data-sharing program is now being administered by the National Center for Health Statistics Research Data Center. The data sharing guidelines have been revised to include comments from interested groups as well as recommendations from the Institute of Medicine (IOM).

The Vaccine Adverse Event Reporting System (VAERS), the VSD, and the Clinical Immunization Safety Assessment (CISA) Network are tools by which the CDC and FDA measure vaccine safety^[2] to fulfill their duty as regulatory agencies charged with protecting the public. Data from the VSD Project have been utilized to address a number of vaccine safety concerns; examples include a study clarifying the risk of anaphylaxis after vaccine administration^[3] and several studies examining the rejected hypothesis of a link between thimerosal-containing vaccines and autism.^[4]^[5]^[6]

Participating healthcare organizations

The following organizations are members of the project:^[7]

Group Health Cooperative of Puget Sound, Seattle, Washington
Harvard Pilgrim Health Care, Boston, Massachusetts
HealthPartners Research Foundation, Minneapolis, Minnesota
Kaiser Permanente Northwest, Portland, Oregon
Kaiser Permanente Medical Care Program of Northern California, Oakland, California
Kaiser Permanente Colorado, Denver, Colorado
Kaiser Permanente of Georgia, Atlanta, Georgia
Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Southern California Kaiser Permanente Health Care Program, Los Angeles, California

Notes

^ Chen RT; Glasser JW; Rhodes PH et al. (1997). "Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team". Pediatrics 99 (6): 765–73. doi:10.1542/peds.99.6.765. PMID 9164767.
^ Centers for Disease Control and Prevention, Vaccine Safety Monitoring at CDC, retrieved 2015-03-11.
^ Bohlke K; Davis RL; Marcy SM et al. (2003). "Risk of anaphylaxis after vaccination of children and adolescents". Pediatrics 112 (4): 815–20. doi:10.1542/peds.112.4.815. PMID 14523172.
^ Geier DA, Geier MR (Spring 2006). "Early Downward Trends in Neurodevelopmental Disorders Following Removal of Thimerosal-Containing Vaccines" (PDF). Journal of American Physicians and Surgeons 11 (1).
^ Verstraeten T; Davis RL; DeStefano F et al. (2003). "Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases". Pediatrics 112 (5): 1039–48. doi:10.1542/peds.112.2.e98. PMID 14595043.
^ Thompson WW; Price C; Goodson B et al. (2007). "Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years". N. Engl. J. Med. 357 (13): 1281–92. doi:10.1056/NEJMoa071434. PMID 17898097.
^ http://www.cdc.gov/vaccinesafety/Activities/VSD.html

External links

NationalAcademies.org - 'Independent Oversight of Vaccine Safety Data Program Needed To Ensure Greater Transparency and Enhance Public Trust', National Academies (February 17, 2005)
WHO.int (pdf) - 'The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA', R.T. Chen, F. DeStefano, R.L. Davis, L.A. Jackson, R.S. Thompson, J.P. Mullooly, S.B. Black, H.R. Shinefield, C.M. Vadheim, J.I. Ward, S.M. Marcy & the Vaccine Safety Datalink Team, World Health Organization

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 健康成人における予防接種に対するアプローチ approach to immunizations in healthy adults
2. 髄膜炎菌ワクチン meningococcal vaccines
3. 小児に対するロタウイルスワクチン rotavirus vaccines for infants
4. Hepatitis B virus immunization in infants, children, and adolescents
5. 小児における標準的な予防接種：親による接種控えと接種拒否 standard childhood vaccines parental hesitancy or refusal

English Journal

Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age.

Ray P, Black S, Shinefield H, Dillon A, Carpenter D, Lewis E, Ross P, Chen RT, Klein NP, Baxter R; for the Vaccine Safety Datalink Team.SourceKaiser Permanente Vaccine Study Center, Oakland, CA, USA.
Vaccine.Vaccine.2011 Sep 2;29(38):6592-6597. Epub 2011 Jul 16.
BACKGROUND: Associations between vaccinations, particularly hepatitis B, and onset of rheumatoid arthritis (RA) have been reported, but examined in few large-scale studies.METHOD: Onset of RA cases and dates of vaccination against hepatitis B, tetanus, and influenza were identified in a retrospectiv
PMID 21763385

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.

Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH, Baxter R, Jacobsen SJ, Irving S, Daley MF, Yin R, Naleway A, Nordin JD, Li L, McCarthy N, Vellozzi C, Destefano F, Lieu TA; Vaccine Safety Datalink Project.SourceCenter for Child Health Care Studies, Department of Population Medicine, Children's Hospital Boston, Boston, Massachusetts, USA. grace_lee@hphc.org
American journal of preventive medicine.Am J Prev Med.2011 Aug;41(2):121-8.
BACKGROUND: The emergence of pandemic H1N1 influenza virus in early 2009 prompted the rapid licensure and use of H1N1 monovalent inactivated (MIV) and live, attenuated (LAMV) vaccines separate from seasonal trivalent inactivated (TIV) and live, attenuated (LAIV) influenza vaccines. A robust influenz
PMID 21767718

「VSD」

　　[★]

「safety」

　　[★]

n.

安全性、安全度

[1] Chen RT; Glasser JW; Rhodes PH et al. (1997). "Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team". Pediatrics 99 (6): 765–73. doi:10.1542/peds.99.6.765. PMID 9164767.

[CDC_Vaccine_Safety-2] Centers for Disease Control and Prevention, Vaccine Safety Monitoring at CDC, retrieved 2015-03-11.

[3] Bohlke K; Davis RL; Marcy SM et al. (2003). "Risk of anaphylaxis after vaccination of children and adolescents". Pediatrics 112 (4): 815–20. doi:10.1542/peds.112.4.815. PMID 14523172.

[4] Geier DA, Geier MR (Spring 2006). "Early Downward Trends in Neurodevelopmental Disorders Following Removal of Thimerosal-Containing Vaccines" (PDF). Journal of American Physicians and Surgeons 11 (1).

[5] Verstraeten T; Davis RL; DeStefano F et al. (2003). "Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases". Pediatrics 112 (5): 1039–48. doi:10.1542/peds.112.2.e98. PMID 14595043.

[6] Thompson WW; Price C; Goodson B et al. (2007). "Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years". N. Engl. J. Med. 357 (13): 1281–92. doi:10.1056/NEJMoa071434. PMID 17898097.

[7] ttp://www.cdc.gov/vaccinesafety/Activities/VSD.html

匿名

検索

案内

案内

Vaccine Safety Datalink